# Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis

> **NCT03421002** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Candidiasis, Systemic
- Candida Meningitis

## Interventions

- **DRUG:** Micafungin

## Key facts

- **NCT ID:** NCT03421002
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-30
- **Primary completion:** 2018-04-10
- **Final completion:** 2018-04-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03421002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03421002, "Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03421002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*